Ramipril
From Pharmacopedia
More actions
Ramipril
Altace
Experience
No personal reports yet
No clinical reports yet
Log in to add your own experience.
Problems
No problems yet. Be the first to suggest one.
+ Add a problemTitration strategies
No titration strategies yet. Be the first to suggest one.
Effects
No effects listed yet. Be the first to suggest one.
Relevant anecdote
No anecdotes yet. Share a relevant one.
Relevant Literature
No literature entries yet.
Log in to submit relevant literature.
Summary
Classes
Common uses
Hypertension0, Heart failure0, Post-myocardial infarction (LV dysfunction)0, Cardiovascular risk reduction in high-risk patients (per HOPE)0
Pharmacy
Starting dose
2.5 mg PO once daily (1.25 mg in CHF or volume depletion); titrate to 5-10 mg/d
Preparations
1.25, 2.5, 5, 10 mg capsules
US FDA Max
20 mg/d (hypertension); 10 mg/d (other indications typical)
Pharmacology
Routes
Oral
Onset
BP effect 1-2 hours; max at 6 hours
Duration
24 hours
Half-life
~13-17 hours (ramiprilat, the active metabolite)[1]
Bioavailability
~28% (oral; food slows but does not reduce absorption)[1]
Pregnancy
Contraindicated in pregnancy (all trimesters); fetal renal injury, oligohydramnios, skull hypoplasia, hypotension[1]
Legal status
Rx-only in US
Purported mechanism
Ramipril is a prodrug hydrolyzed to ramiprilat, a long-acting ACE inhibitor that blocks conversion of angiotensin I to angiotensin II, reducing vasoconstriction, aldosterone secretion, and renal sodium retention.0 The HOPE trial (2000) demonstrated cardiovascular risk reduction in high-risk patients with vascular disease or diabetes, independent of BP lowering — establishing the broader "ACE inhibitors for vascular protection" indication beyond hypertension and heart failure[1].
References
- ↑ 1.0 1.1 1.2 1.3 FDA Prescribing Information, Altace (ramipril), Pfizer/King, current revision. https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/019901s063lbl.pdf